Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
87 articles
Promising Results for Chemo-Free Immunotherapy in Early-Stage Triple-Negative Breast Cancer
Phase 2 trial shows potential for immunotherapy without chemo in early TNBC, especially with high TILs.
Promising Combo Therapy Shows High Response Rate in High-Risk Melanoma
New immunotherapy combo shows 55% major pathologic response in high-risk melanoma, activating immune system
Epigenetic-Immunotherapy Combo Shows Promise in Advanced Pancreatic Cancer
Phase 2 trial combines HDAC inhibitor and PD-1 inhibitor in pancreatic cancer, showing durable responses.
Cannabis Extract Shows Promise in Taming Chemo-Induced Nausea
Oral THC:CBD capsules prove effective against chemotherapy-induced nausea and vomiting in phase II/III trial.
NOBROLA Trial: Olaparib Shows Promise in Rare TNBC Subset Despite Low Enrollment
Phase II trial explores olaparib in TNBC patients with HRD but no BRCA mutations, showing potential benefit.
Unmasking the Risk Factors: New Insights into Immune-Mediated Hepatotoxicity in Cancer Immunotherapy
Meta-analysis reveals key risk factors for liver toxicity in cancer patients receiving immunotherapy
New Hope for Myelofibrosis: Low-Dose Decitabine Shows Promise in Phase 2 Trial
Phase 2 trial reveals potential of low-dose subcutaneous decitabine for treating myelofibrosis cytopenias.
Intensified Chemo Falls Short in Oligometastatic Breast Cancer Study
IACT shows no advantage over CDCT in HRD-positive oligometastatic breast cancer, but long-term survival promising
Immune Checkpoint Inhibitor Rechallenge: A New Hope for Cancer Patients
Meta-analysis shows ICI rechallenge may be safe and effective for some cancer patients who stopped treatment
Sex and Side Effects: New Study Explores Gender Differences in Cancer Immunotherapy
Meta-analysis investigates sex-based differences in adverse events for cancer patients on immunotherapy
PD-L1 Expression Predicts Immunotherapy Benefit in Advanced Gastroesophageal Cancer
Meta-analysis shows PD-L1 levels predict immunotherapy efficacy in gastroesophageal adenocarcinoma
ASC2ESCALATE: Exploring Asciminib's Potential in Early-Stage CML Treatment
Phase II trial evaluates asciminib for first- and second-line therapy in chronic myeloid leukemia.